Category Archives: Biotech

GenQual and R-Pharm collaborate to deliver predictive diagnostics for novel anti-IL-6 antibody for autoimmune diseases

Seattle, WA, San Francisco, CA and Moscow, Russia, 2016-May-25 — /EPR Network/ — R-Pharm and GenQual are pleased to announce a new collaboration focused on the development of novel predictive diagnostic tools in the area of Rheumatoid Arthritis and Autoimmune diseases.

The GenQual proprietary real-time PCR platform, when applied to the genes that are involved in the manifestation of several autoimmune diseases, allows us to detect and assess single nucleotide polymorphisms. Here, allelic determination is used as potential predictor of the treatment response by the novel anti-IL6 antibody, which is currently in development by R-Pharm.

GenQual Founder and CEO Jonathan Mirich said, “This partnership is exciting for GenQual as we advance in our goal to deliver predictive diagnostic tools for the treatment of autoimmune disorders. We are very excited about the possibilities in this space and are thankful to have quality partners in R-Pharm.”

R-Pharm CEO Vasily Ignatiev indicated the importance of the Autoimmune diseases as an area of the development and growth for R-Pharm, as well as the development of novel diagnostic tools aimed to increase the level of predictive response and efficiency of the upcoming treatment paradigm.

About GenQual
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications.  Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level.  GenQual is a privately-held corporation based in Seattle, WA area, USA.

About R-Pharm
R-Pharm is a private Russian pharmaceutical company founded in 2001. It employs over 3,500 highly qualified specialists in 60+ branches. R-Pharm operates in Russia and CIS, USA, Germany, Japan, Turkey/MENA.

The company is involved in R&D, manufacturing (finished dosage forms, biotech and chemical APIs), marketing, sales and distribution of innovative pharmaceutical products in hospital/specialty care therapeutic areas.

R-Pharm collaborates with major international pharmaceutical companies and universities in the fields of drug discovery, development, clinical trials, manufacturing and commercialization.  The company operates several  GMP compliant manufacturing sites in Russia and Germany, research, BD/licensing and marketing affiliates in Japan, Germany, Turkey and US.

Marketed portfolio and pipeline features drugs used in oncology, hematology, autoimmune diseases, HIV, HCV, neurology, diabetes, cardiology, as well as antibiotics, contrast media and anesthesia agents.

Contact

R-Pharm
info@rpharm.ru
www.r-pharm.com/en/

 

GenQual

info@genqual.com
206.659.7825
www.genqual.com

Creative BioMart Launched Thousands of Assay Kits

Creative BioMart, launched a full list of assay kits to the life science community, aiming to provide its customers with the most comprehensive list of products at reasonable prices.

Shirley, NY, USA (February 4, 2016) — Creative BioMart, a world leader in the manufacturing of research-use protein products and custom protein services, launched a full list of assay kits to the life science community, aiming to provide its customers with the most comprehensive list of products at reasonable prices.

An assay is an investigative procedure in laboratory medicine, pharmacology, environmental biology, as well as molecular biology for qualitatively assessing the presence or amount of a target entity. Assay kits, used in life science research, drug discovery & development, and environmental monitoring, have a wide range of applications such as studying disease pathways, screening for potential drug candidates and evaluating biopharmaceutical production processes.

According to the official speaker in Creative BioMart, this new release of assay kits including over 1600 products such as U2OS C3AR1 Bioassay Kit, eXpress C5AR1 Activated GPCR Internalization Assay, CHO-K1 CCR4 Bioassay Kit, etc.

“By supplying the assay kits to biologists, we hope to further support the scientific research.” commented Linna Green, chief marketing staff in Creative BioMart. “Moreover, this release is just a beginning, we will launch more novel assay kits product in the near future. Customers can get the detailed information on our official website. Hope this launch can help promote our customers’ research and save time for them.”

For more detailed information about Creative BioMart’s newly released assay kits, please visit http://www.creativebiomart.net/product/assay-kits_358.htm or contact 1-631-559-9269.

About Creative BioMart
Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development. We are offering more than 1,000 recombinant proteins, peptides and antibodies. All the products are rigorously tested to meet the most demanding research needs. At the same time, lowest prices in the industry are always guaranteed.

Contact Creative BioMart
Address: 45-16 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-559-9269
Email: info@creative-biomart.com
Website: http://www.creativebiomart.net

Biotage® ACT Plate Adapter Prevents Evaporative Cross-Talk

Biotage® (STO: BIOT), announces the launch of Biotage® ACT (Anti Cross Talk) Plate Adapter, an innovative solution for prevention of well to well cross contamination during extract evaporation.

Uppsala, Sweden — Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, announces the launch of Biotage® ACT (Anti Cross Talk) Plate Adapter, an innovative solution for prevention of well to well cross contamination during extract evaporation.

Biotage® ACT Plate Adapter is an essential accessory for evaporation devices. Constructed from robust, high grade anodized aluminum, it fits on top of the 96-well collection plate containing the sample during evaporation. The plate adapter is compatible with straight needle evaporation devices such as the Biotage® SPE Dry 96 and Biotage® SPE Dry Dual systems, and does not require any changes to the existing analytical method.

The Biotage® ACT Plate Adapter is designed to fit on top of the 96-well collection plate, is reusable and easy to use. Evaporated gases are directed away from the sample wells, eddies are reduced, and the plate adapter reduces the open surface area of the top of the wells, lessening the likelihood that material can re-enter and contaminate adjacent wells.

“During evaporation a proportional amount of analytes present in an extracted sample can contaminate surrounding wells by being carried with the volatilized solvent. If the analyte concentration in one well is considerably higher than the analyte concentration in the surrounding wells it has the potential to cause a clinically significant and erroneous change to the adjacent samples. Biotage® ACT Plate Adapter is the first commercially available device to address the issue of cross talk on evaporation” says Dr. Claire Desbrow, Product Manager, Analytical Chemistry, Biotage.

The plate adapter can be incorporated into existing assays without the need for changing any other aspects of the method, and there is minimal impact of solvent drying times.

For further information, visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information at Biotage, please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
Email: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 293 employees with sales of 490 MSEK in 2014. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.

Biotage® Announces EVOLUTE® EXPRESS Columns – Simplified, Fast and Efficient SPE using the Load-Wash-Elute Procedure

Biotage® (STO: BIOT), announces the addition of new polymer based SPE columns to their tried and tested EVOLUTE® EXPRESS range.

Uppsala, Sweden (June 26, 2015) — Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, announces the addition of new polymer based SPE columns to their tried and tested EVOLUTE® EXPRESS range.

EVOLUTE® EXPRESS is a novel family of plates, and now columns, that simplify polymer-based SPE by employing a streamlined three step protocol; Load-Wash-Elute. By using this approach and removing the conditioning and equilibration steps, necessary with traditional bio-analytical SPE procedures, processing and method development times are dramatically reduced without loss of analyte recovery or method robustness.

The EVOLUTE® EXPRESS design provides a uniform flow in the processing of aqueous samples and eliminates the need for re-runs due to clogging. This clear flow technology makes EVOLUTE® EXPRESS particularly efficient and effective when used with SPE automated systems, (such as the Biotage Extrahera™) and enabling consistent, rapid and reliable manual processing.

“Biotage has built a reputation for offering products that simplify Sample Preparation, promoting high throughput and reliability. By expanding the tried and tested EVOLUTE® EXPRESS range we address a real concern for many analysts who have to re-run samples due to well-clogging and sample variability. The minimal three step approach of Load-Wash-Elute considerably improves the way SPE is performed and offers significant time savings for all bio-analysis labs” says Dr. Claire Desbrow, Analytical Chemistry, Product Manager, Biotage.

EVOLUTE® EXPRESS columns are packed with polymer-based EVOLUTE® chemistries (ABN, CX, WCX, AX and WAX) to address most application needs in a wide range of laboratories.

For further information, visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information at Biotage, please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
Email: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 293 employees with sales of 490 MSEK in 2014. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.

Regenexx Announces the Publication of “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” on Amazon Kindle

Broomfield, CO, February 02, 2015 — /REAL TIME PRESS RELEASE/ — With more than 40,000 downloads, “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” is now available on Amazon Kindle. The third edition of the top-selling e-book is being offered as a free download through Jan. 6, 2015.

Written by Dr. Chris Centeno, this e-book delves into the human musculoskeletal system and explains how everything works together in concert to maintain our physical wellbeing. When a single component in this chain is damaged, it can lead to a cascade of joint, spine and connective tissue problems, resulting in chronic pain.

Using the Regenexx SANS approach, Orthopedics 2.0 walks you through a series of tests and exercises that you can do on your own to better understand where your own body is struggling to maintain proper stability and alignment, explaining the possible reasons and long term implications along the way. Orthopedics 2.0 also explores how Regenexx is pioneering the new field of Interventional Orthopedics, where the use of regenerative biologic treatments, such as adult stem cell therapy and platelet rich plasma, are being used to help repair and strengthen damaged tissues, as opposed to invasive surgeries that often remove important tissues when a joint or the spine becomes damaged.

With hyperlinks to more detailed information, related studies and commentary, this book condenses a vast amount of data and resources into an enjoyable and entertaining read.

About Regenexx
Since its genesis in 2005, Regenexx has been a world-leader in the use of adult stem cell treatments for orthopedic conditions, providing non-surgical, biologic therapies delivered with high accuracy through a needle. Regenexx has collected and published more data on stem cell patients than any other company and are dedicated to reinventing orthopedic care to help patients avoid invasive surgery.

Featured on television and media outlets such as the Doctors TV show, ABC News, Good Morning America and many others, Regenexx is taking orthopedic stem cell therapy to an exciting new level.

For more information about this e-book or to talk with a Regenexx Liaison, please call 888-525-3005 or email info@regenexx.com. Visit Regenexx online at:http://www.regenexx.com/

Contact-Details: Regenexx
Contact: Mark Testa
403 Summit Blvd., Suite 201
Broomfield, CO 80021
Phone: 888.525.3005
Email: info@regenexx.com
Web – http://www.regenexx.com/

MEDIA:

PHOTO:

JPEG

ViroCarb’s anti HIV Crowd Funding Campaign

Toronto, Canada, December 01, 2014 — /REAL TIME PRESS RELEASE NEWS/ — ViroCarb Inc. has launched a worldwide crowd funding campaign to promote the development of its new HIV infection inhibitor.

WORLD AIDS DAY – Make a donation to save lives from AIDS! Support new treatment development at: https://www.indiegogo.com/projects/funding-a-new-therapy-against-drug-resistant-hiv/x/9240077

Despite the great progress made in HIV/AIDS treatment, there is still an urgent need for new drugs, particularly for people who have had to abandon existing treatments due to HIV drug resistance and side effects.

The current treatment of HIV/AIDS involves the use of three or more drugs from five main general classes, used in combination. While this antiretroviral therapy (ART) has helped to reduced morbidity and mortality from AIDS, long term toxicity and the emergence and transmission of drug resistant HIV strains limit the effectiveness. Thus, despite therapy which can render this a chronic, rather than acute fatal infection, development of new drugs to prevent infection and overcome drug resistant strains, is increasingly urgent.

ViroCarb Inc. is developing a novel technology that addresses infections by drug resistant HIV strains. Developed from the identification of a new, natural resistance factor against HIV infection by scientists at SickKids and Canadian Blood Services, ViroCarb’s inhibitor works against a previously overlooked target on the virus to block HIV from entering human cells, the very first step in the infection. It works against all HIV strains.

Funds are needed to aid in moving forward to support preclinical studies; therefore ViroCarb Inc. has started an international crown funding campaign to carry out these HIV model studies needed before conducting clinical trials.
Please support this new way to block HIV.

Contact-Details: Dr. Mario Huesca
479 Simonston Boulevard.
Thornhill ON.
L3T 4M4 Canada

Facebook: https://www.facebook.com/ViroCarb;
Website: http://www.virocarb.com

MEDIA:

VIDEO:

New Biotage® SNAP ULTRA C18 Cartridges – High Performance Reversed Phase Flash Purification

Biotage announces the launch of Biotage® SNAP ULTRA C18 – a range of high performance, reversed phase flash purification cartridges and samplets.

Uppsala, Sweden (November 11, 2014) — Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of Biotage® SNAP ULTRA C18 – a range of high performance, reversed phase flash purification cartridges and samplets.

Biotage® SNAP ULTRA C18 reversed phase cartridges are optimized for use with Biotage ACI™ and Isolera™ flash systems and are available in 12 g, 30 g, 60 g, 120 g, 400 g, 950 g and 1850 g cartridge sizes. They enable chemists to confidently load 2-3% weight percentage of samples onto reversed phase columns, a marked improvement when compared to the currently typical 0.5 – 1% loads. The time taken for purification and solvent usage can therefore be reduced by 50% or a smaller cartridge can be used for the same purification, often with improved purification results.

The new reversed phase cartridges are packed with the new, Biotage® HP-Sphere C18 25 micron spherical silica particles that give a boost to resolution with higher purity peaks over standard reversed phase cartridges. The silica is chemically neutral with no adverse interactions, ensuring higher yields and better recoveries; a wide diversity of purifications are possible, including the use of both acidic or basic modifiers.

“It is no longer enough for suppliers to arbitrarily work on single aspects of the workflow and purification – today a more holistic approach is required, one that involves a combination of factors; with this product range we have further augmented the Biotage ACI™ and Isolera™ flash systems and have created a superior product for purification” says Dr. Sunil Rana, Global Product Manager, Biotage.

For further information, visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information at Biotage, please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
Email: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 290 employees with sales of 444.6 MSEK in 2013. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.

Biotage Launches ACI™ – Accelerated Chromatographic Isolation

Biotage announces the launch of ACI™ (Accelerated Chromatographic Isolation), a new advance converting simple flash purification into a faster and more economical way to isolate pure compounds.

Uppsala, Sweden (July 10, 2014) — Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of ACI™ (Accelerated Chromatographic Isolation), a new advance converting simple flash purification into a faster and more economical way to isolate pure compounds.

Biotage believes that ACI™ will radically improve the efficiency of the laboratory, embracing the latest developments in purification technology to guide chemists towards improved chromatography. With running costs a concern in most laboratories, ACI™ will efficiently move users to the end-point even faster. Traditional purification taking more than 15 minutes is reduced to 5 minutes; a 250 mg scale laboratory scale experiment can now be purified in less than 3 minutes on a 10 g column with an ACI™ enabled Biotage Isolera™ flash purification system.

“This is a very exciting and pivotal development, the speed enhancements are akin to the impact felt when microwaves first hit the scene. There is nothing out there that comes close to this system. Chemists will now have freedom to work on other things while they let their ACI™ system do the purification. It is fully automated, reliable and lightning fast, we can completely purify 250 mg of sample in less than 3 minutes, this is quicker than most people take to run the TLC” says Dr Sunil Rana, Global Product Manager, Biotage.

Biotage Isolera™ systems already recommend cartridges based on the sample size and programmed TLC data; they work out the best solvent gradient based on compound, and provide real time indication of eluting compounds, using UV, ELSD or Mass Detection. They subtract signal baselines automatically, so chemists can be confident that the correct fractions are collected.

ACI™ radically improves this, working seamlessly with the Biotage Isolera™ system, the simple wizard quickly guides chemists through the system, beneficial for new users or those whose expertise or priorities lie in synthesis rather than purification. Existing Biotage Isolera systems can be upgraded to ACI™ systems, and ACI™ will come as standard on all new production systems.

For further information visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information from Biotage please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
E-Mail: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 290 employees with sales of 444.6 MSEK in 2013. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.

New 1 mL ISOLUTE® SLE+ 48-well Plates from Biotage – Extract Larger Sample Volumes, Faster

Biotage announces the launch of the new ISOLUTE® SLE+ 1 mL Supported Liquid Extraction 48-well plates, enabling the extraction of larger sample volumes (1 mL total load volume) than presently possible in the microplate footprint.

Uppsala, Sweden (June 30, 2014) — Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of the new ISOLUTE® SLE+ 1 mL Supported Liquid Extraction 48-well plates, enabling the extraction of larger sample volumes (1 mL total load volume) than presently possible in the microplate footprint.

The new ISOLUTE® SLE+ 1 mL sample volume 48-well plates are packed with ISOLUTE SLE+ material; each well containing sufficient ISOLUTE® SLE+ material to efficiently extract 1 mL of aqueous sample. Existing 96-well formats have a maximum capacity of 400 µL, the new plates enable customers to extract larger sample volumes and therefore achieve higher sensitivity, higher throughput and lower detection limits.

The new plates are ideal for the extraction of small molecule drugs, metabolites and endogenous biomarkers from biological fluid samples prior to analytical techniques such as LC-MS/MS and GC-MS. Analytical chemists in clinical, forensic toxicology and Pharmacology will appreciate the high throughput and extra sample capacity.

As with the other products in the ISOLUTE® SLE+ range, the same simple load-wait-elute procedure is used with this new 48-well format reducing method development time.

The plates can be processed using microplate compatible positive pressure manifolds, such as the Biotage® Pressure+ 96, vacuum manifolds such as the Biotage® VacMaster™ 96 and most automated liquid handling systems.

The plate is arranged in a 6 x 8 array; with 48 samples being processed per plate a higher throughput than equivalent column formats is achievable. A new compatible 48-well collection plate is also available with a 5 mL capacity so that the entire elution solvent volume can be collected with no need to swap collection vessels.

For further information visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information from Biotage please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
E-Mail: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 290 employees with sales of 444.6 MSEK in 2013. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.

Biotage Breaks New Ground with Its Fully Integrated Mass Directed Flash System

Biotage announces the launch of the new Isolera™ Dalton – a fully automated miniaturized mass directed flash purification system.

Uppsala, Sweden, June 5, 2013 — Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of the new Isolera™ Dalton – a fully automated miniaturized mass directed flash purification system. The new system raises the bar for flash purification by integrating, for the first time, a miniaturized mass detector and an advanced flash chromatography system into one commercially available platform.

The mass detector and Isolera™ Spektra flash purification system are seamlessly integrated via the Isolera™ Dalton Nanolink unit, an intelligent sampling device which handles all fluids and synching calculations between the two units. Isolera™ Dalton easily fits inside a standard fume hood, requires no external pumps and is capable of both normal and reverse-phase separations, so it is completely compatible with the diverse purification needs of the modern research laboratory.

“Compounds are identified in real time during purification and this informs the flash fractionation process, enabling the correct product to be collected by the system. The system automatically accommodates different column sizes and flow rates, overcoming major issues with simple splitter-based systems. Isolera™ Dalton significantly reduces the number of steps required to purify and confirm a target compound, thus improving workflow and increasing confidence that chemists have synthesized what was intended. Quite frankly there is nothing else like it on the market today or that even comes close”
says Dr Sunil Rana, Global Product Manager, Biotage.

The instrument uses a wizard-based approach to method development, simple on screen prompts guides chemists through the system; even those whose expertise or priorities lie in compound synthesis rather than analysis.

For further information visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10

-Ends-

For further press information at Biotage please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
E-Mail: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical chemistry, medicinal chemistry, separation and purification. The customers include pharmaceutical and biotech companies, companies within the food industry and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has approx. 290 employees and had sales of 463 MSEK in 2012. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: http://www.biotage.com.